- Home
- BIRK vs MIRM Comparison
BIRK vs MIRM Comparison
Compare BIRK & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BIRK | MIRM |
|---|---|---|
| Founded | 1774 | 2018 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0B | 5.7B |
| IPO Year | 2023 | 2019 |
Fundamental Metrics
Financial Performance| Metric | BIRK | MIRM |
|---|---|---|
| Price | $39.35 | $98.77 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 12 |
| Target Price | $62.08 | ★ $115.33 |
| AVG Volume (30 Days) | ★ 2.0M | 747.4K |
| Earning Date | 05-13-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 74.59 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $19,138,000.00 |
| Revenue This Year | $13.76 | $26.22 |
| Revenue Next Year | $14.29 | $22.04 |
| P/E Ratio | $17.48 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $33.06 | $38.22 |
| 52 Week High | $57.39 | $109.28 |
Technical Indicators
Market Signals| Indicator | BIRK | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 57.96 | 59.08 |
| Support Level | $37.73 | $97.49 |
| Resistance Level | $42.19 | $107.51 |
| Average True Range (ATR) | 1.57 | 3.61 |
| MACD | 0.46 | 0.54 |
| Stochastic Oscillator | 87.38 | 95.08 |
Price Performance
Historical ComparisonAbout BIRK Birkenstock Holding plc
Birkenstock is a German footwear brand known for comfort-focused, timeless designs, with 76% of 2022 sales coming from its top five iconic models. Products are made in Europe using sustainable, mostly locally sourced materials. The brand combines orthopedic function with everyday style, appealing to a broad audience. The Americas account for 52% of sales, EMEA 37%, with the remainder coming from Asia-Pacific, which has also the higher future growth expectations.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.